Keywords: Contrast Agents, Tumors
Motivation: Gadolinium based contrast agents have some disadvantages such as deposition in the kidney, brain etc., We developed biocompatible iron based contrast agent for tumor hypoxia imaging.
Goal(s): Evaluation of FOBNI, an iron based hypoxia targeting contrast agent in brain tumor
Approach: The relaxivities of FOBNI were studied at 3, 7, and 9.4 T fields. Further, a group of three rats with brain tumors underwent dynamic imaging with multiple echo scans with FOBNI.
Results: It showed a clear contrast between normal and hypoxic conditions in solution. The percentage signal enhancements in the tumor over 2 hours were analyzed and showed good results.
Impact: The contrast agent FOBNI showed good hypoxia-targeting ability in rat tumors. This will open a new path to developing iron-based hypoxia-targeting agents as an alternative to traditional gadolinium-based contrast agents.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords